Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/PARP14_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/PARP14_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/PARP14_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PARP14_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PARP14_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/PARP14_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PARP14_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/PARP14_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PARP14_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PARP14_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000268312 | Cervix | HSIL_HPV | negative regulation of immune system process | 39/737 | 434/18723 | 1.51e-06 | 6.60e-05 | 39 |
GO:004593615 | Cervix | HSIL_HPV | negative regulation of phosphate metabolic process | 36/737 | 441/18723 | 3.12e-05 | 8.94e-04 | 36 |
GO:001056315 | Cervix | HSIL_HPV | negative regulation of phosphorus metabolic process | 36/737 | 442/18723 | 3.27e-05 | 9.16e-04 | 36 |
GO:000193314 | Cervix | HSIL_HPV | negative regulation of protein phosphorylation | 30/737 | 342/18723 | 3.80e-05 | 1.03e-03 | 30 |
GO:004232614 | Cervix | HSIL_HPV | negative regulation of phosphorylation | 32/737 | 385/18723 | 6.03e-05 | 1.44e-03 | 32 |
GO:00713533 | Cervix | HSIL_HPV | cellular response to interleukin-4 | 7/737 | 33/18723 | 2.48e-04 | 4.30e-03 | 7 |
GO:001922111 | Cervix | HSIL_HPV | cytokine-mediated signaling pathway | 35/737 | 472/18723 | 2.64e-04 | 4.52e-03 | 35 |
GO:00706703 | Cervix | HSIL_HPV | response to interleukin-4 | 7/737 | 36/18723 | 4.38e-04 | 6.51e-03 | 7 |
GO:00507771 | Cervix | HSIL_HPV | negative regulation of immune response | 17/737 | 194/18723 | 1.76e-03 | 1.88e-02 | 17 |
GO:003210211 | Cervix | HSIL_HPV | negative regulation of response to external stimulus | 29/737 | 420/18723 | 2.53e-03 | 2.48e-02 | 29 |
GO:000283111 | Cervix | HSIL_HPV | regulation of response to biotic stimulus | 24/737 | 327/18723 | 2.65e-03 | 2.55e-02 | 24 |
GO:0060759 | Cervix | HSIL_HPV | regulation of response to cytokine stimulus | 14/737 | 162/18723 | 4.88e-03 | 4.02e-02 | 14 |
GO:0001959 | Cervix | HSIL_HPV | regulation of cytokine-mediated signaling pathway | 13/737 | 150/18723 | 6.39e-03 | 4.96e-02 | 13 |
GO:00105632 | Colorectum | MSS | negative regulation of phosphorus metabolic process | 118/3467 | 442/18723 | 1.18e-05 | 2.77e-04 | 118 |
GO:00459362 | Colorectum | MSS | negative regulation of phosphate metabolic process | 117/3467 | 441/18723 | 1.74e-05 | 3.84e-04 | 117 |
GO:00423262 | Colorectum | MSS | negative regulation of phosphorylation | 103/3467 | 385/18723 | 3.76e-05 | 7.17e-04 | 103 |
GO:00019332 | Colorectum | MSS | negative regulation of protein phosphorylation | 93/3467 | 342/18723 | 4.54e-05 | 8.35e-04 | 93 |
GO:0060333 | Colorectum | MSS | interferon-gamma-mediated signaling pathway | 11/3467 | 27/18723 | 6.03e-03 | 4.04e-02 | 11 |
GO:00459363 | Colorectum | MSI-H | negative regulation of phosphate metabolic process | 53/1319 | 441/18723 | 9.54e-05 | 3.01e-03 | 53 |
GO:00105633 | Colorectum | MSI-H | negative regulation of phosphorus metabolic process | 53/1319 | 442/18723 | 1.01e-04 | 3.16e-03 | 53 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PARP14 | SNV | Missense_Mutation | | c.2578C>G | p.Leu860Val | p.L860V | Q460N5 | protein_coding | tolerated(0.53) | benign(0.047) | TCGA-A2-A1FV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyclophosphamide | SD |
PARP14 | SNV | Missense_Mutation | novel | c.2665N>A | p.Glu889Lys | p.E889K | Q460N5 | protein_coding | tolerated(0.14) | benign(0.037) | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PARP14 | SNV | Missense_Mutation | | c.2473N>A | p.Glu825Lys | p.E825K | Q460N5 | protein_coding | deleterious(0.02) | possibly_damaging(0.749) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PARP14 | SNV | Missense_Mutation | | c.4653N>T | p.Met1551Ile | p.M1551I | Q460N5 | protein_coding | tolerated(1) | benign(0.003) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PARP14 | SNV | Missense_Mutation | | c.142N>T | p.Pro48Ser | p.P48S | Q460N5 | protein_coding | tolerated(0.07) | possibly_damaging(0.609) | TCGA-B6-A0RH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
PARP14 | SNV | Missense_Mutation | novel | c.5212N>A | p.Val1738Met | p.V1738M | Q460N5 | protein_coding | tolerated(1) | benign(0) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
PARP14 | SNV | Missense_Mutation | novel | c.2375G>C | p.Cys792Ser | p.C792S | Q460N5 | protein_coding | tolerated(0.19) | benign(0.003) | TCGA-BH-A0HU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
PARP14 | SNV | Missense_Mutation | | c.763N>C | p.Gly255Arg | p.G255R | Q460N5 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-C8-A134-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
PARP14 | SNV | Missense_Mutation | | c.4396G>C | p.Asp1466His | p.D1466H | Q460N5 | protein_coding | tolerated(0.13) | benign(0.048) | TCGA-E2-A1LH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
PARP14 | SNV | Missense_Mutation | | c.3835N>G | p.Gln1279Glu | p.Q1279E | Q460N5 | protein_coding | tolerated(1) | benign(0.372) | TCGA-GM-A2DH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | CR |